Bowel Hot Spots at PET-CT
Authors:
- Dushyant V. SahaniDSDushyant V. Sahani
- Alan J. FischmanAFAlan J. Fischman
- Peter R. MuellerPMPeter R. Mueller
- Michael A. BlakeMBMichael A. Blake
- 1 January 2007
- journal article
- review article
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 27 (1) , 145-159
Abstract
Positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) has been shown to be sensitive in the detection of many bowel malignancies, but its specificity is lower because of various physiologic and pathologic patterns of bowel FDG uptake. PET-computed tomography (CT) can be useful in localizing and characterizing foci of increased FDG uptake within the bowel. As the use of PET-CT in the staging and monitoring of oncologic disease continues to expand, familiarity with these patterns of bowel FDG uptake is essential and can help determine the need for and the relative urgency of further testing. Although a variety of imaging protocols are used for PET-CT, the use of negative oral contrast agent allows improved bowel distention while eliminating potential artifacts caused by high-density oral contrast agents. In addition, correlation with the CT portion of the combined PET-CT examination can sometimes help identify the cause of focal or segmental bowel uptake. The radiologist should be aware of potential pitfalls in the evaluation of FDG-avid foci within the abdomen, including bowel motility and low-attenuation lesions mimicking bowel. Nevertheless, even though the precise role of combined PET-CT for bowel assessment has yet to be determined, the application of sound basic principles of image interpretation will help ensure the accurate interpretation of bowel findings seen with this combined modality.Keywords
This publication has 33 references indexed in Scilit:
- Oral contrast medium in PET/CT: should you or shouldn’t you?European Journal of Nuclear Medicine and Molecular Imaging, 2005
- Clinical Experience with a Commercially Available Negative Oral Contrast Medium in PET/CTRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 2005
- The effect of oral contrast on large bowel activity in FDG-PET/CTAnnals of Nuclear Medicine, 2005
- PET-CT Fusion Imaging in Differentiating Physiologic from Pathologic FDG UptakeRadioGraphics, 2004
- Positron Emission Tomography/Computerized Tomography Functional Imaging of Esophageal and Colorectal CancerThe Cancer Journal, 2004
- Dual-Modality PET/CT Scanning with Negative Oral Contrast Agent to Avoid Artifacts: Introduction and EvaluationRadiology, 2004
- F-18 Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis of Inflammatory Bowel DiseaseClinical Nuclear Medicine, 2001
- 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel diseaseThe Lancet, 1999
- Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.Radiology, 1998
- Inflammatory bowel disease activity measured by positronemission tomographyThe Lancet, 1997